Journal of Community Hospital Internal Medicine Perspectives (Jul 2020)

Man vs. man-made marijuana: A case of drug-induced posterior reversible encephalopathy syndrome (PRES) due to K2, a synthetic cannabinoid (SCB)

  • Priyanka Parajuli,
  • Manjari Rani Regmi,
  • Odalys Estefania Lara-Garcia,
  • Ismael Abu Limon,
  • Alan Deckard

DOI
https://doi.org/10.1080/20009666.2020.1781349
Journal volume & issue
Vol. 10, no. 4
pp. 361 – 364

Abstract

Read online

Synthetic Cannabinoids (SCB) are engineered chemical compounds that share a similar chemical structure with the active ingredient of marijuana, delta-9-tetrahydrocanabinol. Although the FDA has not approved the use of SCB without a prescription from a licensed health-care provider, the cost effectiveness and availability of SCB has made it a popular choice among recreational drug users. Manufacture of SCB as a street drug is not regulated. These SCB are highly potent chemicals that cause various severe toxicities. In this case report, we describe an adult who suffered from PRES after consuming K2, a synthetic cannabinoid.

Keywords